Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. We actively explore new options for patients including novel compounds, small molecules and biologics, and through cannabinoid science and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.
The Director, Hem/Onc Marketing will play a key role within the Business Unit – leading the marketing team for an exciting and impactful product in the AML-space – Vyxeos. The candidate will be responsible for directly managing a team of marketers – office and field-based, and for leading a cross-functional brand team – setting and pulling through a clear brand vision, strategic plan, and operating plan. The candidate will also be a key member of the Marketing and Hematology/Oncology leadership team.
This individual will:
Required Knowledge, Skills, and Abilities
Required/Preferred Education and Licenses
Description of Work Environment
Jazz Pharmaceuticals is an equal opportunity/affirmative action employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any characteristic protected by law.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing, and commercializing meaningful products that address unmet medical needs.
We have a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology. We also support commercial products in other therapeutic areas where we can meaningfully address serious medical needs.
As part of our unwavering commitment to improve patients’ lives, we are continuing to expand our commercial product portfolio and our research and development pipeline in therapeutic areas that can leverage our unique expertise. We do this through a growth strategy of growing sales of the existing medicines in our portfolio; acquiring commercial products or product candidates that are in late-stage development; and pursuing focused development of our pipeline of differentiated therapies.
10,000 employees or more